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Brain involvement in myotonic dystrophy type 1 (DM1) is
characterized by heterogeneous cognitive, behavioral, and
affective symptoms and imaging alterations indicative of
widespread grey and white matter involvement. The aim of
the present study was to systematically review the literature
on brain pathology in DM1. We conducted a structured
search in EMBASE (index period 1974–2017) and
MEDLINE (index period 1887–2017) on December
11, 2017, using free text and index search terms related to
myotonic dystrophy type 1 and brain structures or regions.
Eligible studies were full-text studies reporting on micro-
scopic brain pathology of DM1 patients without potentially
interfering comorbidity. We discussed the findings based on
the anatomical region and the nature of the anomaly. Neu-
ropathological findings in DM1 can be classified as follows:
(1) protein and nucleotide deposits; (2) changes in neurons
and glial cells; and (3) white matter alterations. Most find-
ings are unspecific to DM1 and may occur with physiologi-
cal aging, albeit to a lesser degree. There are similarities
and contrasts with Alzheimer’s disease; both show the
appearance of neurofibrillary tangles in the limbic system
without plaque occurrence. Likewise, there is myelin loss
and gliosis, and there are dilated perivascular spaces in the
white matter resemblant of cerebral small vessel disease.
However, we did not find evidence of lacunar infarction or
microbleeding. The various neuropathological findings in
DM1 are reflective of the heterogeneous clinical and neuro-
imaging features of the disease. The strength of conclusions
from this study’s findings is bounded by limited numbers of
participants in studies, methodological constraints, and lack
of assessed associations between histopathology and clinical
or neuroimaging findings.
Key words: brain, microscopic pathology, myotonic dystro-
phy, systematic review.
INTRODUCTION
Myotonic dystrophy type 1 (DM1) is a complex multi-
system disease, caused by a cytosine–thymine–guanine
(CTG) microsatellite repeat expansion in the 30-
untranslated region of the dystrophia myotonica protein
kinase (DMPK) gene, that has autosomal dominant inheri-
tance.1 DM1 is a chronic progressive disease characterized
by reduced survival, high burden of disease, and loss of
quality of life.2,3 Brain involvement in DM1 is phenotypi-
cally heterogeneous.4 Features include variable combina-
tion of developmental disorders, cognitive deficits in
various domains, personality and behavioral disturbances,
affective symptoms, and sleep disorders.5–7 These clinical
features of brain involvement in DM1 are accompanied by
alterations in structural and functional brain imaging, as
summarized in several recent reviews.8–10
Despite progress in the understanding of brain corre-
lates of these non-motor manifestations of DM1, partly
due to increasingly sophisticated imaging techniques, less
is known about pathological alterations that underly these
now well-recognized clinical and imaging phenotypes in
DM1. Various histopathological features have been
observed in postmortem brain samples of patients with
DM1.4 In the current study, we systematically reviewed
the published literature on microscopic brain alterations in
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the human DM1 brain. A thorough and comprehensive lit-
erature review was conducted to identify gaps in the pre-
sent knowledge and to inform future studies evaluating
microscopic brain alterations in DM1. These goals com-
port with suggestions and advice recently formulated by
the scientific community in DM1.11,12 Therefore, the aim
of this study was to provide a systematic overview of the




We conducted a systematic review of the literature and,
where possible, aggregated homologous data. Prior to the
commencement of data analysis, we registered the proto-
col of this study in PROSPERO, an international prospec-
tive register of systematic reviews, under ID 42018085626.
It can be accessed at: http://www.crd.york.ac.uk/
PROSPERO/display_record.php?ID=CRD42018085626.
A single author (RW) conducted a search in EMBASE
(index period 1974–2017) and MEDLINE (index period
1887–2017) on December 11, 2017. AC, JR, and BK
supervised the search, which was conducted in collabora-
tion with an information specialist of the university library.
We used free text and index search terms related to myo-
tonic dystrophy type 1 and brain structures or regions
(Appendix I). Additional studies were identified through
cross-referencing. Because we were unaware of the num-
ber, sizes, and types of studies to expect, we modified the
eligibility criteria during the course of the study, as we felt
the initial criteria to be too restrictive or too loose (see
Appendix II).
Eligibility criteria and study selection
Studies were eligible if they reported on at least one
microscopic pathological brain feature in ≥ 1 patient with
confirmed clinical or genetic DM1 diagnosis according to
the authors and no evidence of potentially relevant
co-morbidity (i.e. brain disease other than DM1) that
could interfere with outcomes of interest. We excluded
studies for reasons as follows: (1) unavailability of full text;
(2) language of publication other than English, Dutch,
French, or German; (3) double reporting (i.e. dual publi-
cation of same research results); and (4) conference
abstracts. After deduplication, study selection comprised
an initial round of title and abstract screening, followed by
a second round of full-text screening. Both screening
rounds were independently performed by two authors
(RW and KO). Differences in the selection of studies were
discussed to meet consensus.
Data extraction
Data extraction was carried out independently by RW and
KO. We extracted the following data from each selected
study: study characteristics (first author, year of publica-
tion, brain areas, and pathological alterations under
study); patient characteristics (number, sex, age at death,
DM1 disease class, and clinical or genetic DM1 diagnosis).
DM1 disease class was defined as either congenital, infan-
tile, juvenile, adult, or late-onset DM1. Where applicable,
we also collected these variables for healthy or disease
control subjects that were presented in the included
studies.
Data synthesis
To summarize our findings, we classified the pathological
alterations reported in the included studies and counted
the number of studies reporting these pathological alter-
ations. Accordingly, we subdivided our results on the basis
of the most frequently reported alterations.
RESULTS
Search and selection results
Our primary search resulted in a total of 2099 records
(Fig. 1). After deduplication and title and abstract screen-
ing, a total of 102 records remained for full-text screening.
We excluded 63 studies, mostly for reasons of absence of
outcome of interest (n = 40), unsuitable publication type/
conference abstract (n = 17), and language restriction
(n = 5). We included 39 studies from our primary search
and included an additional two studies after cross-
referencing, making a total of 41 studies (Fig. 2).13–53
Fig 1 Literature search and study selection with a flow chart of
literature search and study selection. *See text for reasons for
exclusion. This figure has been created using Microsoft Visio
2007, saved in .jpg image format.
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Study characteristics
A total of 130 DM1 patients were included in 41 studies
(Table 1). However, as some research groups assessed dif-
ferent pathological aspects in studies on identical subjects
(e.g. the group of Ono and colleagues), the number of
unique subjects is likely considerably lower. Most studies
included a limited number of participants; the largest
series investigated the brain of 17 patients and the median
number of patients was five. Healthy (n = 292) and disease
controls (n = 598) were present in 23 and 16 studies,
respectively. The most frequently included disease con-
trols were patients with Duchenne muscular dystrophy
(n = 253, two studies), Alzheimer’s disease (n = 56, 11
studies), amyotrophic lateral sclerosis (n = 28, six studies)
and progressive supranuclear palsy (n = 30, five studies).
The most common pathologic features were: (1) protein
or nucleotide deposits; (2) cellular alterations in neurons
or glial cells; and (3) white matter alterations. For each
feature, the relevant study and brain structures in which
they were present are shown in Table 2.
PROTEIN AND NUCLEOTIDE DEPOSITS
Intracytoplasmic eosinophilic thalamic inclusion
bodies
A total of 14 studies examined post-mortem neuropatho-
logical samples of 66 patients for the presence of thalamic
inclusion bodies (TI) (Table 2). These thalamic inclusion
bodies are round to oval structures located in the cyto-
plasm of neurons that stain homogeneously eosinophilic
with HE staining. Anti-ubiquitin antibody positivity and
tau negativity have been demonstrated with immunohisto-
chemical methods.31 No more than one to two TI were
present per neuron. They were not found in post-mortem
brains of patients with congenital DM1 that died at a
young age.17,23 They were found in a variable number
(18–100%) of adult DM1 patients and in a variable per-
centage of thalamic cells (3.5–35%), depending on the
study. TI were not specific to DM1 as has been found in
unaffected controls and controls with other degenerative
brain diseases, although the percentage of affected neu-
rons in DM1 exceeded that in the control populations.19
The latter finding was not present in a previous study on
TI, in which the number of inclusions was higher in
healthy controls than in one DM1 patient.17
Marinesco bodies in the substantia nigra
A total of six studies evaluated the presence of Marinesco
bodies (MB) in the substantia nigra neurons in post-
mortem brains of 31 patients.19,26,34,42,45,48 Marinesco bod-
ies are eosinophilic intranuclear bodies in the pigmented
neurons of the substantia nigra (Fig. 3). MBs are not spe-
cific to DM1, as they have been observed in other brain
diseases, such as Alzheimer’s and amyotrophic lateral scle-
rosis, and in physiological aging.19,42 MB may be accompa-
nied by eosinophilic intracytoplasmic inclusion bodies that
Fig 2 Country of origin of studies. The world map shows country of origin of brain pathology studies in DM1. All studies originate
from a total of seven countries. The map has been created with Mapchart.net (https://mapchart.net/) under a CC BY-SA 4.0 license.
© 2021 The Authors. Neuropathology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of
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highly resemble thalamic inclusion bodies at the structural
and ultrastructural (i.e. electron microscopy) level.19 As
with these intracytoplasmic antibodies, immunohistochem-
istry has demonstrated anti-ubiquitin antibody positivity of
MB. Whereas one study found a higher load of MB in
DM1 patients compared to controls with systemic or neu-
rodegenerative disease,19 equal loads in patients versus
controls were found in substantia nigra neurons in another
study.42
Neurofibrillary tangles
A total of 19 studies reported on the presence or absence
of tau pathology in 104 DM1 patients (Table 2). Most
studies detected neurofibrillary tangles (NFT) in all or
most of the patients that were evaluated.22,43,45,47,49
Reportedly, the brain areas that demonstrated the highest
burden of neurofibrillary tangles (NFTs) were the entorhi-
nal cortex, (subdivisions of) the hippocampus, the para-
hippocampal cortex, the temporal cortex, and the
amygdala. Other, often less affected areas included the
olfactory bulb,20 brain stem,45,47 basal ganglia,20,47
cerebellum,45 and other (non-temporal lobe) parts of the
neocortex20,34,43,45,49 The load of NFTs was higher in DM1
patients than in controls in three studies.22,45,47 In contrast
to the aforementioned studies, Moriuchi et al.24 found
NFT in only two out of 17 DM1 patients, and Ono et al.19
found no or few NFTs in the hippocampus in DM1
patients. Studies reported no or incidental “plaques”
accompanying the tau-related neuropathological
changes.20,22,32,34,45,47 Studies demonstrated that the NFT
in DM1 are preferentially composed of tau proteins
devoid of the amino acids encoded by exons 2 and 3 of
the microtubule associated protein tau (MAPT)
gene.32,45,49
Nuclear accumulations
Two studies demonstrated the presence of abnormal,
mutant RNA accumulations in the nucleus of brain cells
using fluorescence in situ hybridization techniques.44,53
These accumulations have been coined “RNA foci.” Jiang
et al.44 observed these foci diffusely throughout the brain
of adult DM1 patients, in neurons of the cortex, hippo-
campus, thalamus, and brainstem, including the substantia
nigra. Of note, the cerebellum displayed small foci in the
Purkinje cells but not in neurons of the molecular or gran-
ule cell layer. Foci were sometimes multiple and were also
occasionally observed in oligodendrocytes of white matter
in subcortical and callosal areas.44 More recently, Michel
et al.53 demonstrated RNA foci GVD in the temporal cor-
tex that coincided in the human brain in the earliest (i.e.
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Other accumulations
Four studies (total n = 17) noted the presence of
granulovacuolar degeneration (GVD), involving electron-
dense granules within double membrane-bound
cytoplasmic vacuoles, in the temporal lobe/hippocampal
area of DM1 patients.19,26,50,51 GVD were also found in
other neurodegenerative diseases.50 Ono et al.19 (n = 4
patients) found few GVD in the hippocampal area, and
two out of five patients from the study by Oyanagi et al.26
had “several” GVD in the temporal cortex that coincided
with NFTs and Hirano bodies. In hippocampal pyramidal
neurons, one group demonstrated a strong relationship
between GVD and tau pathology.50,51 Skein-like
ubiquitin-positive inclusions in the striatum were observed
in aging controls and in patients with various neurodegen-
erative disease, including five out six patients with myo-
tonic dystrophy type 1.40
CELLULAR ALTERATIONS
Neuronal loss
In four post-mortem cases of children with congenital
onset DM1, no neuronal loss was found in the brain on
autopsy.21 In adults, severe neuronal loss was demon-
strated in a proportion of patients as follows: (1) dorsal
raphe nucleus and superior central nucleus of the
Table 2 Summary of histopathological changes, brain regions, and studies
Histopathological changes Number of
studies
Study IDs Brain regions
1. Accumulations of material
Intracytoplasmic eosinophilic
inclusion bodies
14 2; 3; 5; 7; 8; 11; 14; 19;
20; 21; 22; 25; 27; 36
Thalamus
BG; BS: SN
Marinesco bodies 6 7; 14; 22; 30; 33; 36 SN
Neurofibrillary degeneration 19 7; 8; 10; 12; 14; 20; 22; 25;
26; 27; 31; 33; 34; 35; 36; 37; 38; 39; 40
Limbic system: amygdala; HPC; CC;
limbic Cortex; olfactory bulb
CB; BG; NBM; BS: raphe;
hypothalamus
WM
Granulovacuolar degeneration 4 7; 14; 38; 39 HPC; CC: temporal
Plaques 10 7; 8; 10; 14; 20; 22; 26; 35; 36; 40 Whole brain with focus on limbic system
and BS
RNA foci 2 32; 41 CC; HPC; CB; thalamus; BS: SN
WM: subcortical, callosal
Other accumulations 6 14; 25; 28; 30; 35; 36 CC: temporal; thalamus; CB; BG; BS:
pons (locus coeruleus), medulla, SN
2. Cellular alterations
Neuronal alterations 21 1; 2; 4; 8; 9; 10; 12; 13; 15; 16; 17;
18; 22; 23; 24; 25; 27; 29; 30; 36; 40
Limbic system (CC: entorhinal; HPC)
CC; BG; NBM; BS: SN, raphe nuclei,
hypoglossal nucleus; medullary arcuate
nucleus, MRF; CB
WM
Glial alterations 15 2; 4; 6; 8; 9; 16; 17; 22; 25; 30; 36; 40 Limbic system (CC: entorhinal cortex;
HPC; olfactory bulb; amygdala)
CC; thalamus; BG; NBM; CB; BS:
raphe nuclei, medullary pyramids, SN,
LC; hypothalamus
WM
3. White matter pathology 14 4; 6; 9; 10; 11; 13; 22; 25;
27; 31; 32; 34; 36; 40
WM: deep; subcortical; callosal
The most/best studied brain regions are indicated in bold font. BG, basal ganglia; BS, brain stem; CB, cerebellum; CC, cerebral cortex; HPC, hip-
pocampus; LC, locus coeruleus; MRF, medullary reticular formation; NBM, nucleus basalis of Meynert; SN, substantia nigra; WM, white matter.
Fig 3 Hitological features of an MB in the substantia nigra.
Black arrowhead depicts a Marinesco body (an eosinophilic
structure) adjacent to a similar-sized nucleolus (a basophilic struc-
ture). This image is kindly provided by Dr. Kusters.
© 2021 The Authors. Neuropathology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of
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midbrain; (2) pontine raphe and pontine reticular forma-
tion; and (3) dorsal medullary central nucleus, ventral
medullary central nucleus, medullary arcuate nucleus, and
subtrigeminal medullary nucleus in the medulla.28–30,41
The authors noted this neuronal loss in the brainstem in
association with hypersomnia and hypoventilation.28,30 In
contrast, Mizukami et al.,37 Itoh et al.,48 and Lidang Jensen
et al.27 reported no loss of neurons in the (pontine and
medullary) brain stem. In the substantia nigra, mild neuro-
nal loss was observed in two case reports34,37; two case
series demonstrated neuronal loss in zero out of seven and
two out of 11 patients in this region.42,48 Similarly, neuro-
nal loss was observed in the cerebellum in the case in Miz-
ukami et al.37 but absent in two case series on 11 and nine
patient evaluating cerebellar granule and Purkinje cells,
respectively.48,52 In the cerebral cortex, Maurage et al.45
(n = 3), Abe et al.25(n = 1), Ono et al.41 (n = 8), Watanabe
et al.34 (n = 1), and Lidang Jensen et al.27(n = 2) observed
no neuronal loss. Other studies observed cortical neuronal
loss in a variable proportion of patients: Mizukami et al.37
(one out of one), Itoh et al.48 (six out of 11), and Jinnai
et al.52 (seven out of nine). Cortical neuronal atrophy was
observed by Yoshimura et al.20 and Watanabe et al.34 The
basal ganglia did not demonstrate neuronal loss.25,34,48 We
did not find studies that evaluated neuronal loss in the
thalamus. In the hippocampus, mild neuronal loss was
found by Watanabe et al.34 (n = 1) but not by Ono et al.41
(n = 8) and Itoh et al.48 (n = 11). In the adjacent entorhi-
nal cortex, however, neuronal loss was observed by Jinnai
et al.52 (9 out of 9) and Itoh et al.48 (6 out of 11). Neuronal
loss was also found in the nucleus basalis of Meynert,34,37
and in the locus coeruleus.37,48 With two exceptions,30,41
most studies did not report how neuronal loss was specifi-
cally evaluated. Neuronal loss was quantified qualitatively
or semi-quantitatively. The study by Ono et al.,41 in which
design-based stereological techniques were used, is a nota-
ble exception.
Neuronal heterotopia
Heterotopic neurons were found in the white matter in
three studies13,21,34 that evaluated the brains from nine
patients. Four brains were from patients with congenital
DM1 that died shortly after birth; the other five were from
DM1 patients that deceased at ages 36 to 51. Heterotopic
neurons were found both in subcortical and deep white
matter.
Reactions of glial cells
Eight studies evaluated the presence of gliosis in the brain
of 37 DM1 patients. In the two largest studies (n = 11 and
n = 9), gliosis was observed diffusely throughout the deep
white matter.48,52 Itoh et al.48 also found astrogliosis in two
out of 11 brains in the locus coeruleus and substantia
nigra. In contrast, Kumada et al.42 observed no gliosis in
the substantia nigra in any of seven brains. Ono et al.
found gliosis in six out of eight patients in the raphe nuclei
and superior central nucleus of the brainstem that accom-
panied neural loss.28,29 Yoshimura et al.20 and Mizukami
et al.37 observed cortical gliosis. In the case described by
Yoshimura et al.,20 cortical gliosis was accompanied by dif-
fuse gliosis throughout the brain, including the cerebellum,
the brain stem, and the limbic system. In another case
report, no cortical gliosis was found.34 Studies did not typi-
cally specify the type of gliosis (e.g. reactive astrogliosis,
microgliosis/activated microglia cells, or oligodendrocyte
response).
WHITE MATTER PATHOLOGY
Various neuropathological findings in white matter were
reported in 14 studies (Tables 1 and 2). There was loss of
myelin from deep and subcortical white matter, and wid-
ened perivascular spaces (Figs 4,5), giving the white mat-
ter an “état criblé” appearance. The largest study (n = 11)
reported loss of axons accompanying the myelin loss,48
whereas in two case reports myelin loss coincided with
“relative axonal sparing.”25,37 Itoh et al.48 also found capil-
lary hyalinization and fibrillary gliosis.
DISCUSSION
The various and anatomically diffuse microscopic brain
alterations in myotonic dystrophy type 1 are a reflection of
the heterogeneous clinical features and imaging character-
istics of brain involvement of the disease (Fig. 6). On the
basis of our findings, we classified microscopic brain
pathology in DM1 as: (1) protein and nucleotide deposits;
(2) cellular anomalies; and (3) white matter pathology
(which will be discussed in more detail in the next
sections).
Protein and nucleotide deposits
The presence of various deposits has been noted in histo-
pathologic studies in DM1. The first descriptions include
the intracytoplasmic eosinophilic bodies in the thalamus
and the MBs in the substantia nigra. Their clinical rele-
vance is uncertain, as MB could be found in persons as
young as 21 years of age and are not associated with a spe-
cific disease.55 However, their prevalence in the substantia
nigra increases with age and they could be considered as a
marker for neurodegeneration.56 Immunohistochemically,
MB are generally positive for proteins of the ubiquitin–
proteasome system.57 Their increased occurrence in the
substantia nigra in DM1, if validated in controlled, larger
studies, might imply a relationship between protein
© 2021 The Authors. Neuropathology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of
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degradation systems, abnormal proteins resulting from
aberrant splicing in DM1, and neurodegeneration. Inter-
estingly, echography studies have demonstrated hyper-
echogenicity of the substantia of the substantia nigra in a
proportion of DM1 patients, in comparison to controls.58
Furthermore, the presence of accumulations and neuronal
loss in the brainstem (see below) is interesting in light of
abnormal levels of dopamine and serotonin metabolites in
the cortex and the brain stem, respectively, in animals
studies.59 These findings invite the study of in vivo
(i.e. CSF) and ex vivo neurotransmitter metabolism in
DM1-affected individuals.
More recently, the demonstration of RNA “foci,” toxic
accumulations of mutant RNA, in the brain provide a
direct link between the molecular pathophysiology of
DM1 and visible histopathological alterations.44,53 The
CTG repeat expansion in the 30-untranslated region of the
DMPK is transcribed into long CUG-containing mRNAs
that remain in the nucleus and may sequestrate RNA-
binding proteins and, consequently, lead to transcriptional
dysregulation.60 The formation of these alterations is
likely located upstream in the cascade of pathophysiologi-
cal brain changes in DM1, and they have been shown to
start very early in the disease process. Interestingly, the
development of brain “foci” is well captured in animal
models and, consequently, is an aspect that is open to
future therapeutic study in DM1.
Tau protein is encoded by a single gene (MAPT) on
chromosome 17q21 and represented by different isoforms
generated by alternative splicing from the MAPT gene.
An expanding spectrum of diseases now classified as
“tauopathies” is characterized by NFTs that consist of
aggregates of hyperphosphorylated and abnormally phos-
phorylated isoforms of tau proteins.61,62 In several of the
tauopathies, aberrant splicing of the MAPT RNA has
been demonstrated, and aberrant alternative tau splicing
Fig 4 Perivascular dilatation in the cerebrum. In the temporal lobe, enlarged perivascular spaces are observed on sections, stained
Klüver–Barrera, from a DM1 patient (B) but not a control individual (A).
Fig 5 Perivascular dilatation in the cerebrum. Enlarged peri-
vascular spaces are identified by polarized light imaging in the
same patient as in Figure 4.
© 2021 The Authors. Neuropathology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of
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could promote tau pathology.63 Tau missplicing results in
isoform-specific impairment in normal physiological function
and enhanced recruitment of excessive tau isoforms into the
pathological process.63 In DM1, recent work has suggested
an interplay between toxic RNA, disordered splicing, and
the dysregulation of microtubule-associated protein tau.64,65
In DM1, the “foci,” consisting of accumulations of toxic
RNA, are known sequester RNA-binding proteins, such as
splicing factors, consequently leading to dysregulated alter-
native splicing in neurons.64,65 Accordingly, alterations of
tau alternative splicing have been reported in DM1 with
missplicing of exons 2 and 6 in the brain. Thus, DM1 is
characterized by the preferential accumulation of the 0N3R
isoform.32 Moreover, several studies provide evidence of the
effects of missplicing on tau aggregation, protein–protein
interactions, microtubule stabilization, and axonal transport,
which may be relevant to myotonic dystrophy type 1.64,65
In DM1, neurofibrillary degeneration (NFD) is preferen-
tially seen in parts of the limbic system including (parts of)
the hippocampus and adjacent cortex, but other brain regions
may also show signs of tau pathology. Clinical features of
DM1, such as diminished olfaction, apathy, and learning and
memory disorders may reflect involvement of the limbic sys-
tem;5,66,67 however, the exact relation with NFD in this area
is unknown. It should be noted that tau pathology can be
present in brains of individuals that have shown healthy aging
from a clinical perspective, and that tau missplicing is not
restricted to tauopathies but can also be present in non-tau
proteinopathies.62,63 It remains to be seen to what extent tau
pathology in DM1 is causal to the heterogeneous brain phe-
notypes of the disease. Besides this uncertainty about the
clinicopathological correlations, the spatiotemporal progres-
sion of NFD in DM1 is undiscovered at present. PET-Tau
imaging offers a means to study such progression in vivo and
could be applied to DM1 in future studies.68 In addition, the
relationship of tau pathology with other histopathological fea-
tures of DM1 should be further studied. Understanding the
pathophysiology of DM may increase our knowledge of the
complexity of the pathological interplay among RNAopathy,
spliceopathy, and proteinopathy implicated in tauopathies
and other neurodegenerative diseases.65
Cellular alterations
Neuronal loss in the brainstem was inconsistently present
across studies. Neuronal loss in the brainstem may relate to
clinical features of excessive daytime sleepiness and ventila-
tory dysfunction.28,29 Brainstem neuronal loss was not cap-
tured in a DM mouse model with respiratory dysfunction.69
In the cerebellum, neuronal loss has been the subject of lim-
ited study but does not seem to be a generalized finding. In
common with other trinucleotide repeat expansion, somatic
instability (i.e. increase in size) of the CTG repeat was lower
in cerebellar tissue than in other brain regions.70 Of note,
most structural imaging studies (voxel-based volumetry and
diffusion tensor imaging) are less suitable for the study of
the brain stem and the cerebellum in comparison to the
hemispheral grey matter. However, alterations in brainstem
Fig 6 Summary of brain imaging findings. †Inconsistent findings across studies. BS, brain stem; CB, cerebellum; CC, cerebral cortex;
HPC, hippocampus; SN, substantia nigra; WM, white matter. Brain MRI slice images are provided by Nevit Dilmen, used under Attri-
bution-ShareAlike 3.0 Unported (CC BY-SA 3.0) license [https://creativecommons.org/licenses/by-sa/3.0/deed.en], downloaded from
commons.wikimedia.org.
© 2021 The Authors. Neuropathology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of
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raphe echogenicity in DM1, noted by Krogias and col-
leagues, may be a possible correlate to brainstem histopath-
ological changes.58 In the cerebral cortex, histopathological
results were mixed, with some studies demonstrating no
neuronal loss and others only in a proportion of patients.
Cortical neuronal loss is in line with magnetic resonance
spectroscopy studies that found decreased concentrations of
N-acetylaspartate, mostly in cortical grey matter. Possible
explanations for the divergent findings between studies may
include heterogeneous patient populations, (unrecognized)
co-morbidities, and technical reasons. Importantly, with few
exceptions, neuronal loss was “quantified” in a qualitative
(i.e. present/absent) or semi-quantitative manner in all stud-
ies. Although gross changes may be detected with these
methods, the number of a specific cell type cannot be simply
deduced from the number of cross-sectional profiles found
in thin tissue sections, as this parameter also depends on cell
volume, tissue orientation, and tissue atrophy.71,72 Conse-
quently, pending more advanced studies, these results on
neuronal loss should be interpreted with caution. In contrast
to studies on neuronal loss, we found no studies that evalu-
ated synaptic density in the brain of DM1 patients. Such
studies would be of interest, as imaging studies have found
grey matter volume loss throughout the cortex in human
DM1 patients.73,74 One correlate of grey matter volume loss
based on voxel-based-morphometry could be neuronal loss,
but given the findings in this study, this is unlikely the only
explanation. Reduced synaptic density may provide a com-
plementary explanation that could be worth exploring.75 In
cell and animal models, there is evidence that the CTG
repeat expansion of DM1 may affect synaptogenesis and
synaptic function.59,76 Finally, as a developmental alteration,
heterotopic neurons may be found in the white matter of
DM1 patients. Their clinical relevance in relation to central
nervous system features of congenital and infantile-onset
DM1 is currently unknown.
White matter changes
Degenerative characteristics of white matter include loss
of myelin in combination with a varying amount of axonal
loss, dilation of perivascular spaces, gliosis, and capillary
hyalinization in deep and subcortical white matter. These
findings are in line with white matter alterations captured
with in vivo neuroimaging: dilated perivascular spaces,
T2/FLAIR hyperintensities, and alterations in micros-
tructurem, as demonstrated with DTI imaging.74,77,78
Although the white matter histological alterations in DM1
share characteristics with cerebral small-vessel disease,
other characteristics of the latter, such as microbleeds and
lacunes, have not been observed in DM1. Consequently,
chronic brain ischemia seems unlikely to be the major
mechanism through which white matter lesions originate.
Renard et al. (2018) proposed increased burden due to
microvascular changes and lack of drainage of interstitial
fluid and degraded protein products as a mechanism for
anterior temporal white matter lesions in DM1.79 This
hypothesis was based on the co-localization of dilated peri-
vascular spaces and white matter hyperintensities in the
anterior temporal pole, which DM1 shares with the mono-
genetic small vessel disease cerebral autosomal dominant
arteriopathy with subcortical infarcts and leu-
koencephalopathy (CADASIL).79,80 Of interest, dilated
perivascular spaces were recently demonstrated to be
associated with the burden of neurofibrillary tangles in
Alzheimer’s disease.81 At the basis of the association of
dilated perivascular spaces with various tauopathies,
including DM1 and Alzheimer’s disease, could be a com-
mon pathophysiological mechanism (e.g. astrocytic dys-
function) worth further exploring.
CONCLUSION
Summarizing our results, clinical and neuroimaging het-
erogeneity of DM1 reflect the various histopathological
changes in DM1. Arbitrarily, histopathological findings
can be classified as: (1) protein and nucleotide deposits;
(2) cellular alterations including neuronal loss and gliosis;
and (3) white matter pathology. We observed both anom-
alies that could be considered developmental in nature
(e.g. heterotopic neurons) and neurodegeneration. Indeed,
many of the neuropathological findings in DM1 share sim-
ilarities with other neurodegenerative diseases and can be
seen in “physiological” aging (albeit to a lesser degree).
The latter findings are compatible with the concept of
DM1 as a progeroid/accelerated aging disease.82,83 How-
ever, in common with the highly variable and unique
admixture of clinical brain features in DM1, the specific
combination of histopathological findings seems to be
unique. For some aspects such as neurofibrillary degenera-
tion, great progress has been made in linking the patho-
physiological concepts of RNAopathy and spliceopathy to
histopathological changes.64 These interrelations remain
elusive for other pathological findings at this time.
In a seminal editorial on “myotonic dystrophy as a
brain disorder”, Ashizawa (1998, p. 291)noted that “avail-
ability of brain autopsy materials in DM is limited and the
MR imaging data are difficult to correlate with the histo-
logical findings.”84 Unfortunately, some 20 years later, we
must conclude that this has not changed. Most published
studies are case reports and small case series. These stand
in sharp contrast to a large and increasingly sophisticated
body of literature on neuroimaging in DM1.8,9 However,
studies that correlate in vivo neuroimaging with
post-mortem histopathological findings are virtually non-
existent. Clearly, there is great need for larger follow-up
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studies that evaluate the associations between the many
neuroimaging findings and microscopic alterations in rela-
tion to clinical DM1 features. Furthermore, more detailed
morphometric studies of animal model brains would
inform us of which aspects of the human DM1 histopathol-
ogy are captured by the (mouse) models. To facilitate such
studies, international collaboration with an established set
of clinical and imaging variables and a logistical pipeline
that allows identical handling (e.g. design-based stereology
for morphometric aspects) of brain autopsy samples is
essential and should be high on the DM1 scientific
research agenda.11,12
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APPENDIX I: MODIFICATIONS TO THE
ORIGINAL STUDY PROTOCOL
1. In the original study protocol, we only included studies
with patients with genetically proven DM1. This crite-
rion was modified to the criterion presented in Appen-
dix III. Because a lot of our studies were published
before or shortly after the discovery of the DMPK gene
in 1992, we felt that this item was too restrictive as we
had to exclude approximately 50% of otherwise eligible
studies based on this criterion.
2. In the original study protocol, we included studies that
obtained results exclusively by macroscopic and/or
genetic examinations. This criterion was modified to
the criterion presented in Appendix III. We felt that
the inclusion of studies on each study level
(i.e. macroscopic, microscopic, and genetic) would be
too extensive. We decided to focus on microscopic
alterations and excluded those that did not present at
least one microscopic outcome.
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PubMed (836 hits) EMBASE (1263 hits)
(“Myotonic Dystrophy”[Mesh] OR Curschmann*[tiab]
OR Dystrophia Myotoni*[tiab] OR Dystrophic Myoton*
[tiab] OR Myotonia Atrophica*[tiab] OR Myotonia
Dystrophi*[tiab] OR Myotonic Dystroph*[tiab] OR
Steinert*[tiab] OR Steinert’s[tiab])
AND
(“Brain”[Mesh] OR “Myelin Sheath”[Mesh] OR
Amygdal*[tiab] OR Brain[tiab] OR Brains[tiab] OR
Brainstem*[tiab] OR Caeruleus[tiab] OR Callos*[tiab]
OR Cerebr*[tiab] OR Ceruleus[tiab] OR Coeruleus
[tiab] OR Corpus Callos*[tiab] OR Cortex*[tiab] OR
Cortical[tiab] OR Cortices[tiab] OR Corticospinal*[tiab]
OR Diencephal*[tiab] OR Encephal*[tiab] OR
Epithalam*[tiab] OR Fascicul*[tiab] OR Glia[tiab] OR
Glial[tiab] OR Gray Matter*[tiab] OR Grey Matter*
[tiab] OR Hippocamp*[tiab] OR Hypothalam* [tiab]
OR Limbic*[tiab] OR Lymbic*[tiab] OR Mesencephal*
[tiab] OR Mesolimbic*[tiab] OR Metencephal*[tiab]
OR Midbrain*[tiab] OR Myelencephal*[tiab] OR
Olfactory Pathway*[tiab] OR Parahippocampal*[tiab]
OR Perforant Nerve Tract*[tiab] OR Perforant Path*
[tiab] OR Telencephal*[tiab] OR Ventricl*[tiab] OR
Ventricul*[tiab] OR White Matter*[tiab])
(myotonic dystrophy/ OR (Curschmann* OR Dystrophia
Myotoni* OR Myotonia Atrophica* OR Myotonia
Dystrophica* OR Myotonic Atroph* OR Myotonic
Dystroph* OR Steinert* OR Steinert’s).ti,ab,kw.)
AND
(exp brain/ OR exp. brain tissue/ OR exp. brain ventricle/
OR myelin/ OR myelin sheath/ OR perforant nerve tract/
OR (Amygdal* OR Brain OR Brains OR Brainstem*
OR Caeruleus OR Callos* OR Cerebr* OR Ceruleus OR
Coeruleus OR Corpus callos* OR Cortex* OR Cortical
OR Cortices OR Corticospinal* OR Diencephal* OR
Encephal* OR Epithalam* OR Fascicul* OR Glia OR
Glial OR Gray Matter* OR Grey Matter* OR
Hippocamp* OR Hypothalam* OR Limbic* OR Lymbic*
OR Mesencephal* OR Mesolimbic* OR Metencephal*
OR Midbrain* OR Myelencephal* OR Olfactory
Pathway* OR Parahippocampal* OR Perforant Nerve
Tract* OR Perforant Path* OR Telencephal* OR
Ventricl* OR Ventricul* OR White Matter*).ti,ab,kw.)
APPENDIX II: SEARCH STRINGS FOR ELECTRONIC DATABASES
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APPENDIX III: EXCLUDED STUDIES, CLASSIFIED BY REASON FOR EXCLUSION
Number First author Year Journal Notes
Language restrictions
1 Tomi H 1986 Clinical Neurology Article in Japanese
2 Mitake S 1989 Rinsho Shinkeigaku Article in Japanese
3 Yoneyama S 1992 Rinsho Shinkeigaku Article in Japanese
4 Haranaka M 2000 No To Hattatsu Article in Japanese
5 Iwata T 2009 Rinsho Shinkeigaku Article in Japanese
Conference abstracts
1 Dhaenens C 2009 Medizinische Genetik
2 Gourdon G 2009 Medizinische Genetik
3 Kang Y 2009 Medizinische Genetik
4 Kuru S 2010 Neuropathology
5 Saito Y 2010 Neuropathology
6 Caillet-Boudin M 2011 Alzheimer’s and Dementia
7 Ikeda K 2011 Neuropathology
8 Jinnai K 2011 Neuropathology
9 Kuru S 2011 Neuropathology
10 Matsuda M 2012 Neuropathology
11 Imanishi A 2013 Sleep
12 Komene T 2013 Neuropathology
13 Oya Y 2013 Neuropathology
14 Servais L 2015 Neuromuscular Disorders
15 Iwasaki Y 2016 Clinical Neurology
16 Sano T 2016 Clinical Neurology
17 Shioya A 2016 Clinical Neurology
Cell/tissue culture studies
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